ASCEND BY NTHRYS
Research Abroad Products

Molecular Oncology Project Topics

Browse all focused areas across all project categories under this field.

Showing 61–72 of 220 project topics
Metabolic Profiling SaaS Platform for Oncology Drug Screening
A cloud-based platform that analyzes real-time metabolic signatures in cancer cells to predict drug efficacy and resistance mechanisms. Enables pharma companies to accelerate lead optimization and reduce clinical trial failure rates by 40-60% through early metabolic biomarker identification.
Cancer Metabolism Molecular Drug Target Platforms Click to view more details →
AI-Powered Lactate Metabolism Inhibitor Discovery Engine
An artificial intelligence platform that identifies and optimizes novel lactate pathway inhibitors targeting tumor microenvironment acidification in solid cancers. Generates $50M+ annual licensing deals by providing biotech firms with validated preclinical candidates ready for IND applications.
Cancer Metabolism Molecular Drug Target Platforms Click to view more details →
Glutamine Addiction Biomarker Detection and Companion Diagnostic Kit
A molecular diagnostic tool that identifies glutamine-dependent tumors and predicts response to GLS inhibitors through multi-omic profiling. Creates recurring revenue through companion diagnostic licensing and enables precision oncology pricing strategies worth $5K-15K per patient test.
Cancer Metabolism Molecular Drug Target Platforms Click to view more details →
Fatty Acid Oxidation Inhibitor Lead Optimization Software Suite
Enterprise software that designs and validates FAO-targeting small molecules using quantum computing and machine learning for structure-activity relationship modeling. Reduces synthesis cycles by 70% and generates $2M-5M annual software licensing fees from major pharmaceutical companies.
Cancer Metabolism Molecular Drug Target Platforms Click to view more details →
Tumor Immunometabolism Phenotyping Platform for Cell Therapy
A high-throughput profiling system that characterizes metabolic reprogramming in CAR-T and TCR-engineered cells to optimize manufacturing and persistence. Supports $20M+ cell therapy manufacturing contracts by enabling metabolic quality control and predictive potency assays.
Cancer Metabolism Molecular Drug Target Platforms Click to view more details →
Warburg Effect Exploiting Prodrug Activation Platform Technology
A proprietary platform technology that designs prodrugs activated specifically by high glycolytic flux in cancer cells, minimizing systemic toxicity and off-target effects. Creates intellectual property licensing opportunities valued at $10M-50M per asset through enhanced therapeutic windows and reduced side effects.
Cancer Metabolism Molecular Drug Target Platforms Click to view more details →
Mitochondrial Dynamics Drug Target Validation and Screening Service
A contract research service providing functional validation of OPA1, DRP1, and MFN-targeting therapeutics in patient-derived xenografts and organoids. Generates $500K-2M per engagement by reducing drug candidate attrition and enabling differentiated positioning for small molecule and genetic programs.
Cancer Metabolism Molecular Drug Target Platforms Click to view more details →
Cholesterol Synthesis Pathway Inhibitor Biomarker Stratification Tool
A genomic and proteomic profiling tool that predicts SREBP2 pathway dependency in hormone-sensitive and resistant cancers for HMGCR inhibitor combination therapy. Generates $3M-8M annual revenue through biomarker licensing, patient stratification services, and companion diagnostic royalties.
Cancer Metabolism Molecular Drug Target Platforms Click to view more details →
Amino Acid Transporter-Targeting Drug Discovery and Validation Platform
An integrated platform combining structure-based drug design, functional transport assays, and metabolic dependency screening for LAT, ASCT2, and xCT family inhibitors. Enables $15M-40M upfront partnerships with global pharma by providing validated series and clear clinical differentiation strategies.
Cancer Metabolism Molecular Drug Target Platforms Click to view more details →
Metabolic Synthetic Lethality Prediction Engine for Combination Oncology
A machine learning platform that identifies metabolic synthetic lethal interactions between cancer driver mutations and anti-metabolic drugs to optimize combination regimens. Drives $8M-20M in annual licensing and royalty revenue by enabling rationally designed combination therapies with reduced toxicity and enhanced efficacy.
Cancer Metabolism Molecular Drug Target Platforms Click to view more details →
AI-Powered Tumor Microenvironment Profiling Platform
A cloud-based SaaS platform that analyzes immune cell composition and spatial distribution within tumor samples using machine learning algorithms. Enables pharma companies to accelerate immunotherapy patient stratification and biomarker discovery, reducing development timelines by 30-40% and improving clinical trial success rates.
Molecular Oncology Immunotherapy Development Click to view more details →
Neoantigen Discovery and Immunogenicity Prediction Engine
Software-as-a-service tool that identifies patient-specific neoantigens and predicts their immunogenic potential using deep learning models trained on clinical response data. Generates recurring revenue through subscription licensing to CAR-T, TCR-T, and personalized vaccine developers seeking rapid candidate identification.
Molecular Oncology Immunotherapy Development Click to view more details →